Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Use of T-VEC in early metastatic melanoma

ESMO 2018

19 - 23 Oct 2018

Published: 21 Oct 2018

Views: 3276

Rating:

Save

Ms Viola Franke - Netherlands Cancer Institute, Amsterdam, Netherlands

Viola Franke speaks with ecancer at ESMO 2018 in Munich about results from a trial using engineered virotherapy talimogene laherparepvec (T-VEC) in early metastatic melanoma.

She describes the significant response rates and low toxicity in this early trial, with followups planned to monitor the ongoing survival of these patients.

For more on melanoma news from ESMO, watch our interview with Dr Alexander van Aakooi.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related Videos

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini

ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )

ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer

Prof Karim Fizazi, Dr Anders Bjartell, Dr Niven Mehra and Prof Eleni Efstathiou

ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Karim Fizazi, Dr Anders Bjartell, Dr Niven Mehra and Prof Eleni Efstathiou )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

Multiple myeloma In Rwanda: The need for further research

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Multiple myeloma In Rwanda: The need for further research ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer

Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer ( Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA )

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

More from ecancer